Caribou Biosciences (CRBU) Current Deferred Revenue (2020 - 2026)
Caribou Biosciences (CRBU) posted quarterly Current Deferred Revenue of $2.6 million for Q1 2026, down 6.61% year-over-year from $2.8 million in Q1 2025, and up 39.42% quarter-over-quarter from $1.9 million in Q4 2025.
Caribou Biosciences (CRBU) Current Deferred Revenue (2020 - 2026) Analysis & Trends
Caribou Biosciences (CRBU) has reported Current Deferred Revenue for 7 consecutive years, with $2.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Deferred Revenue fell 6.61% year-over-year to $2.6 million; the TTM figure through Mar 2026 stood at $2.6 million (down 6.61% YoY), while the FY2025 annual figure was $1.9 million, down 39.44% from the prior year.
- Current Deferred Revenue climbed to $2.6 million in Q1 2026 per CRBU's latest filing, from $1.9 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $31.1 million in Q2 2023 and bottomed at $1.9 million in Q4 2025.
- Historically, Current Deferred Revenue has averaged $8.8 million across 5 years, with a median of $6.8 million in 2024.
- Annual changes were most pronounced in 2022 — Current Deferred Revenue soared 25184.0% — and 2023, when it tumbled 89.0%.
- Caribou Biosciences' Current Deferred Revenue stood at $25.9 million in 2022, then sank by 89.0% to $2.8 million in 2023, then gained by 9.91% to $3.1 million in 2024, then slumped by 39.44% to $1.9 million in 2025, then surged by 39.42% to $2.6 million in 2026.
- Business Quant data shows CRBU's Current Deferred Revenue at $2.6 million in Q1 2026, $1.9 million in Q4 2025, and $2.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Caribou Biosciences | 166.63 Mn | 54.31 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.79 Mn |
| Mar 31, 2026 | 2.64 Mn |
| Dec 31, 2025 | 1.90 Mn |
| Sep 30, 2025 | 2.22 Mn |
| Jun 30, 2025 | 2.83 Mn |
| Mar 31, 2025 | 2.83 Mn |
| Dec 31, 2024 | 3.13 Mn |
| Sep 30, 2024 | 6.78 Mn |
| Jun 30, 2024 | 7.43 Mn |
| Mar 31, 2024 | 8.26 Mn |
| Dec 31, 2023 | 2.85 Mn |
| Sep 30, 2023 | 2.83 Mn |
| Jun 30, 2023 | 31.12 Mn |
| Mar 31, 2023 | 10.88 Mn |
| Dec 31, 2022 | 25.89 Mn |
| Sep 30, 2022 | 12.04 Mn |
| Jun 30, 2022 | 12.64 Mn |
| Mar 31, 2022 | 12.84 Mn |
| Dec 31, 2021 | 30.74 Mn |
| Sep 30, 2021 | 100,000.00 |